<i>PICALM-MLLT10</i> fusion gene in hematological neoplasms: clinical features, current practices, and prognoses
Patients with <i>PLCALM-MALLT10</i> can be diagnosed as AML, ALL, MPAL, and other extremely rare hematological malignancies, with mixed clinical manifestations and poor survival. Novel and intensive therapies, including hematopoietic stem cell transplantation, chimeric antigen receptor T-cell immunotherapy, and targeted agents such as the Bcl-2 inhibitor, could be considered in the future.
Authors
- Yongxian Hu (ORCID: https://orcid.org/0009-0009-9154-0072)
- Fei Cheng (ORCID: https://orcid.org/0000-0003-0557-3951)
- B Ye (ORCID: https://orcid.org/0000-0002-2699-8919)
- Jinuo Wang
- Yang Li (ORCID: https://orcid.org/0000-0002-7677-9028)
- Wenjun Wu
- Jian Yu (ORCID: https://orcid.org/0000-0002-8704-1571)
- Gaofeng Zheng
- Zhen Cai (ORCID: https://orcid.org/0009-0001-5822-7502)
Institutions
- Cell Technology (China) (HK)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Hematology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1080/16078454.2024.2423324
- Citations
- 3
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- National Natural Science Foundation of China